FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

FDA监管成分

该成分是FDA批准或监管的。未经有效处方购买可能违反联邦法律。请在您所在地区核实所有法律规定。

Dulaglutide

Trulicity

Weight Loss & Metabolic

Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.

作用机制

GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.

研究协议

仅供研究使用,非医疗建议。

Research protocols use 0.75mg weekly, escalating to 1.5mg weekly after 4 weeks. Maximum studied dose is 4.5mg weekly.

研究笔记

Clinical Research Status

Dulaglutide received FDA approval in 2014 for type 2 diabetes and has been studied in the extensive AWARD clinical trial program spanning multiple comparator studies. The REWIND cardiovascular outcomes trial demonstrated a 12% reduction in MACE in a broad population including primary prevention patients. It is not currently approved for weight management as a standalone indication.

Key Published Findings

The AWARD trials showed HbA1c reductions of 0.8-1.6% depending on comparator and population studied. REWIND was notable for enrolling a majority of patients without established cardiovascular disease, demonstrating broader preventive benefit. Weight loss in diabetes trials averaged 1.5-3 kg, modest compared to newer GLP-1 agonists optimized for obesity.

Safety Profile

Gastrointestinal adverse events (nausea, diarrhea, vomiting) are the most common side effects, occurring in 15-25% of patients during titration. The same class-wide MTC boxed warning applies, based on rodent thyroid C-cell tumor findings. Injection site reactions are generally mild, and the pre-filled pen device has high patient satisfaction scores.

Comparison to Related Compounds

Compared to semaglutide, dulaglutide produces less weight loss and slightly less HbA1c reduction but uses a simpler auto-injector device that some patients prefer. Its large molecular size (approximately 63 kDa) prevents oral bioavailability, unlike semaglutide which has an oral formulation. Relative to liraglutide, the weekly dosing of dulaglutide offers significant convenience advantage with comparable efficacy.

Community Observations

Trulicity's pen device is frequently cited as one of the most user-friendly among injectable GLP-1 agonists, requiring no needle handling. Patients transitioning from dulaglutide to semaglutide for greater weight loss often report stronger GI side effects initially. Some endocrinologists continue prescribing dulaglutide for patients who prioritize injection simplicity and have modest weight loss goals.

半衰期

~5 days

复溶

Pre-filled pen (no reconstitution)

存储

冻干

Refrigerate 2-8C. Do not freeze.

复溶后

Room temperature up to 14 days if needed.

美国法律状态

FDA-approved (Rx only)

又称作

Trulicity

常见问题

什么是 Dulaglutide?

Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.

Dulaglutide 如何起作用?

GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.

Dulaglutide 在美国的监管状态是什么?

FDA-approved (Rx only)

Dulaglutide 的半衰期是多少?

~5 days

Dulaglutide 还有哪些名称?

Trulicity

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明